0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Cell > LIGHT > SCCHO-ATP109

CHO/Human LIGHT Stable Cell Line Development Service

Order Now

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The CHO/Human LIGHT Stable Cell Line was engineered to express full length human LIGHT (Gene ID: 8740). Surface expression of human LIGHT was confirmed by flow cytometry.
  • Application

    • Useful for cell-based LIGHT binding assay

    • Useful as LIGHT-expressing target cells in reporter gene assay

     LIGHT Assay Principles

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    F-12K + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 LIGHT FACS

Expression analysis of human LIGHT on CHO/Human LIGHT Stable Cell Line by FACS.
CHO/Human LIGHT Stable Cell Line or negative control cell were stained with PE-labeled anti-Human LIGHT

Signaling Bioassay
 LIGHT SIGNALING

Response to human HVEM (FOLD).
This cell was incubated with Human HVEM (Luc) HEK293 Reporter Cell (Cat. No. CHEK-ATF105). The human LIGHT overexpressing on CHO cells can activate HVEM signaling with the max induction fold 227.59.

Passage Stability
 LIGHT PASSAGE

Passage stability analysis of receptor expression by FACS.
Flow cytometry surface staining of human LIGHT on CHO/Human LIGHT Stable Cell Line demonstrates consistent mean fluorescent intensity across passage 4-24

Please contact us if you are interested in related cell pool service.

  • Background
    Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.
  • Limited Use&License Disclosure
    1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

Comments (0)


Voraussichtlicher Liefertermin für vorrätige Produkte: 2 Arbeitstage

Price(EUR) : €3540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:1 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Nachricht schicken